Biology and Therapy of Myeloid Malignancies Conference

Biology and Therapy of Myeloid Malignancies Conference is organized by Fusion Conferences Ltd and will be held from May 14 - 17, 2025 at Avra Imperial Hotel & Conference Center, Chania, Crete, Greece.

Description:
This first ever Fusion Conference focused on the biology and therapy of Myeloid malignancies aims to bring together leading experts to discuss the latest advancements and current challenges in this rapidly evolving field. This conference will provide a comprehensive overview of basic, translational, and clinical research, highlighting the collaborative efforts to improve our understanding and treatment of myeloid malignancies. This is a fast-evolving area, where significant strides have been made in uncovering the molecular and genetic foundations of the large variety of myeloid neoplasms and also pre-neoplastic conditions. Also, it is an area that has been marked by a number of technologic advances, including in computational analysis, single cell sequencing and spatial omics mapping in different tissues and microenvironments. The meeting will also highlight efforts to translate basic research findings into clinical applications.

Sessions will showcase novel biomarkers for early diagnosis, prognosis, and treatment monitoring, including the use of minimal residual disease (MRD) markers. Innovative preclinical models, such as patient-derived xenografts and organoids, will be discussed, illustrating their utility in testing new therapeutic agents. The development of targeted therapies, including FLT3, IDH1/2, Menin inhibitors and BH3 mimetics, will be discussed and mechanisms of response and resistance will be analyzed. Moreover, the Conference welcomes clinical presentations that provide updates on recent clinical trials and emerging therapeutic strategies. The meeting will explore combination therapies that integrate targeted agents with traditional chemotherapies or immunotherapies, aiming to enhance efficacy and overcome resistance. Managing treatment-related toxicities and the importance of supportive care in improving patient outcomes will also be addressed. A highlight will be the exploration of immunotherapies, such as chimeric antigen receptor (CAR) T-cell therapy, bispecific antibody treatments and immune checkpoint inhibitors. Such treatments have shown promise in other blood cancer and are now being actively investigated for myeloid malignancies. The challenges of immune evasion mechanisms in these cancers will be examined, emphasizing the need for combinatorial approaches to optimize the effectiveness of such immune-focused treatments. The meeting will also focus on future research directions in our field. The need for multidisciplinary collaborations to integrate insights from basic, computational, translational, and clinical research will be emphasized. Emerging technologies, such as spatial sequencing, advanced imaging techniques or CRISPR/Cas9 editing approaches, to mention a few, will be discussed. Additionally, the importance of patient-centric research, incorporating patient-reported outcomes and quality of life measures, will be highlighted.

In summary, this meeting aims to provide a comprehensive update on the current status of the area of myeloid malignancy. By showcasing the dynamic interplay between basic discoveries and clinical applications, the conference will underscore the progress made in understanding and treating these complex diseases while also identifying ongoing challenges and future research needs. The event will serve as a platform for fostering collaboration and advancing the field.